ClinicalTrials.gg
CompletedNCT07613684Updated May 29, 2026

Single and Multiple Ascending Dosing Administration of MF-300 in Healthy Participants

A Phase 1 interventional study of MF-300 SAD and Placebo in Healthy Volunteers, sponsored by Epirium Bio Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-29.

Sponsored by Epirium Bio Inc. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Oct 2025, 1 year 1 month ago, and no results have been posted to the registry.
  • Registered 1 year 4 months after the study started (first participant enrolled Dec 2024, registered May 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The study will consist of 2 parts, Study Parts 1 (1a: single ascending dose [SAD] Phase; and 1b: Food Effect Phase) and Part 2 (multiple ascending dose [MAD] Phase). The SAD and MAD phases will evaluate separately non-elderly (≥ 18 to ≤ 65 years of age) and elderly (> 65 to ≤75 years of age) healthy adult subjects.

Read the detailed description

Part 1a is a double blind, randomized, placebo controlled, sequential SAD trial in healthy male or female volunteers. Volunteers will receive oral study drug (MF-300 or placebo) single dose administration. The dose levels will be tested sequentially until safety evaluation identifies a non-tolerated dose in the investigated population or when sustained MF-300 plasma levels are reaching the exposure supported by the available preclinical toxicokinetic data. Approximately 5 dose groups (non-elderly population) will provide a series increasing dose levels. An additional SAD dose group will evaluate an elderly population, with a dose selected based on safety and PK data from the 5 non-elderly SAD cohorts but not higher than what has been determined as generally safe and tolerated in the non-elderly population. Overall, no less than 48 subjects (assuming 6 cohorts of 8 subjects each) may complete the SAD study.

One tolerated dose completed in Part 1a will be selected for the evaluation of food effect (Part 1b). The dose will be selected on the basis of accumulated safety and PK information from the SAD phase. Food effect assessment is to be performed using the non-elderly population only. The food effect study is a randomized, 2-period, 2-sequence, open-label, crossover study. Approximately 12 subjects will be randomly assigned to 1 of the 2 treatment sequences (6 subjects per sequence) in which they receive MF-300 following a 10-hour fast or following a high-fat breakfast.

Part 2 is a double blind, randomized, placebo controlled, sequential MAD trial in healthy male or female volunteers. Volunteers will receive oral study drug (MF-300 or placebo) daily for 5 days as anticipated to achieved MF-300 steady state. The frequency of administration (once daily (QD)) and the duration of therapy required to achieve steady state (5 daily doses) were selected on the basis of allometric modeling from available toxicokinetic data but may be adapted based on MF-300 PK observed in the SAD cohorts previously completed. Three dose groups (non-elderly population) will provide a series increasing dose levels. The start of the MAD and SAD parts will be staggered, and a MAD dose cohort may be initiated when the corresponding SAD cohort at the next higher MF-300 dose has been cleared as safe and the food effect cohort has been completed. A fourth MAD dose group will be evaluated in the elderly population.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • SAD
  • MAD
  • Food Effect
  • Non-Elderly
  • Elderly
03

In context

Lead sponsor

Epirium Bio Inc. is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Non-Elderly Cohorts:

  1. Healthy male or non-pregnant, non-lactating female subjects ≥ 18 to ≤ 65 years of age at time of first dosing.
  2. (BMI) within the range ≥ 18.0 to ≤ 35.0 kg/m2.
  3. Subjects in the food effect cohort must be willing to eat a high fat breakfast, including butter and turkey bacon or sausage.
  4. Female subjects must either:

    1. have no by reason of surgery (e.g., hysterectomy, bilateral oophorectomy, salpingectomy in documented medical history) or be at least 1 year (e.g., 12 months without menstrual period without other medical cause), and have menopause confirmed with follicle-stimulating hormone level of >40 IU/L at screening in women not taking hormone or hormone replacement therapy. Note: Documentation can come from the study center personnel's: review of the subject's medical records, medical examination, or medical history interview.
    2. if of child-bearing potential, must be truly abstinent of heterosexual intercourse as their usual and preferred lifestyle practicing abstinence and agree to remain abstinent for the duration of the study or subject's heterosexual partner is non-fertile (e.g. at least 90 days post-vasectomy from screening) or subjects are using and willing to continue using two medically acceptable forms of birth control for at least 30 days prior to screening (at least 90 days for oral and transdermal contraceptives) and at least 30 days after the last study drug administration. Acceptable forms of contraception include: bilateral tubal ligation or occlusion, oral or injectable hormonal contraceptives, contraceptive patch, hormonal and non-hormonal intra uterine devices, vaginal hormonal rings, vaginal diaphragm, or cervical caps, in addition to having their male partner use a condom plus spermicide agent.
  5. Male subjects must be non-fertile, vasectomized (vasectomy performed 4 months or more prior to the first dosing), or truly abstinent of heterosexual intercourse as their usual and preferred lifestyle and agree to remain abstinent for duration of study and for 90 days from last administration of study drug or heterosexual partner is not of child bearing potential or subject is willing to continue using two medically acceptable form of birth control from Day -1 until at least 90 days after the last administration of study drug. Highly effective contraceptive methods include:

    1. Use of a condom plus spermicide agent from the time of until 90 days after the last administration of study drug.
    2. Subject's sexual partner is of non-childbearing potential, i.e., post-menopausal or surgically sterilized
    3. If subject's partner is of childbearing potential, she is using an acceptable form of contraception such as: bilateral tubal ligation or occlusion, oral or injectable hormonal contraceptives, contraceptive patch, hormonal and non-hormonal intra uterine devices, vaginal hormonal rings, vaginal diaphragm, or cervical caps
  6. Male subjects must agree not to donate sperm from the first dosing until 90 days after the last dose.
  7. Capable of giving signed informed consent that includes agreement to comply with the requirements and restrictions listed in the ICF and in this protocol.

Elderly Cohorts:

To be eligible for this study, subjects must meet all of the following inclusion criteria:

  1. Healthy male or non-pregnant, non-lactating female subjects > 65 to ≤ 75 years of age at time of first dosing. Subjects with a history of and/or current well-controlled medical conditions may be enrolled so long as the investigator, in consultation with the medical monitor, are of the opinion that such conditions will not interfere with the safety of the subjects and that the subjects are otherwise in good general health. Some examples of allowable well-controlled medical conditions, in otherwise healthy subjects, include, but are not limited to the following:

    1. Well-controlled hypertension, for which, if on medication, are on a stable dose for at least 3 months prior to screening with no history of cardiac arrhythmia
    2. Well-controlled pre-diabetes/non-insulin dependent type 2 diabetes managed by diet and exercise. If treated with metformin, on a stable metformin dose for at least 3 months prior to screening
    3. Well-controlled hyperlipidemia, for which, if on medication, are on a stable dose for at least 3 months prior to screening
    4. Overweight/Obesity not requiring medication
  2. Body mass index (BMI) within the range ≥ 18.0 to ≤ 35.0 kg/m2.
  3. Female subjects must have no childbearing potential by reason of surgery (e.g., hysterectomy, bilateral oophorectomy, salpingectomy in documented medical history) or be at least 1 year post-menopausal (e.g., 12 months without menstrual period without other medical cause), and have menopause confirmed with follicle-stimulating hormone level of >40 IU/L at screening in women not taking hormone contraceptive or hormone replacement therapy. Note: Documentation can come from the study center personnel's: review of the subject's medical records, medical examination, or medical history interview. Female subjects who do not meet a follicle-stimulating hormone level of >40 IU/L at screening must be truly abstinent of heterosexual intercourse as their usual and preferred lifestyle and agree to remain abstinent for the duration of the study, or subject's heterosexual partner is non-fertile (e.g. at least 90 days post-vasectomy from screening), or agrees to use a condom plus spermicide agent from screening to end of study.
  4. Male subjects must be non-fertile, vasectomized (vasectomy performed 4 months or more prior to the first dosing), or truly abstinent of heterosexual intercourse as their usual and preferred lifestyle and agree to remain abstinent for duration of study and for 90 days from last administration of study drug or heterosexual partner is not of child bearing potential or subject is willing to continue using two medically acceptable form of birth control from Day -1 until at least 90 days after the last administration of study drug. Highly effective contraceptive methods include:

    1. Use of a condom plus spermicide agent from the time of informed consent until 90 days after the last administration of study drug.
    2. Subject's sexual partner is of non-childbearing potential, i.e., post-menopausal or surgically sterilized
    3. If subject's partner is of childbearing potential, she is using an acceptable form of contraception such as: bilateral tubal ligation or occlusion, oral or injectable hormonal contraceptives, contraceptive patch, hormonal and non-hormonal intra uterine devices, vaginal hormonal rings, vaginal diaphragm, or cervical caps
  5. Male subjects must agree not to donate sperm from the first dosing until 90 days after the last dose.
  6. Capable of giving signed informed consent that includes agreement to comply with the requirements and restrictions listed in the ICF and in this protocol.

Exclusion criteria

Exclusion Criteria:

Non-Elderly Cohorts:

Subjects who meet any of the following criteria will be excluded from participating in the study:

  1. History of or current medical illness including, but not limited to, any cardiovascular disease (including blood pressure or rhythm disturbance requiring constant monitoring), hematologic disease, coagulation disorders, lipid abnormalities, significant pulmonary disease, including bronchospastic respiratory disease and diabetes mellitus, hepatic or renal insufficiency, thyroid disease, neurologic or psychiatric disease, or any other illness that the Investigator considers should exclude the subject or that could interfere with the safety of the subjects, or might confound the study results.
  2. Has cancer (Note: subject with history of cancer that is in complete remission and not requiring treatment for at least 5 years, including basal cell carcinoma, squamous cell skin cancer, or melanoma in situ superficial skin lesions that have been successfully removed, will not be exclusionary).
  3. Has acute or chronic GI conditions (e.g., gastroesophageal reflux disease, peptic ulcer, active and chronic colitis, cholecystectomy, small or large bowel resection, gastric bypass or equivalent) that would interfere with drug tolerance or absorption.
  4. Has history of migraine headaches requiring medical attention or active treatment within the past 6 months from screening.
  5. Has visible sunburn at admission
  6. Has a history of /photosensitivity dermatosis within the past 5 years,
  7. Has another active dermatological pathology at screening or admission excluding dry skin or acne, deemed clinically significant by the Investigator.
  8. Has a history of or active ocular pathology or clinically significant findings in the Investigator opinion on ophthalmology exam at screening (Note: normal slit exam (glaucoma, cataract) will be sufficient to exclude sensitivity to phototoxicity).
  9. Clinically significant abnormalities in results of laboratory tests, such as clinically significant abnormal hematology, clinical chemistry, thyroid, or urinalysis at screening or at the time of admission, as per Investigator's judgment; Note: Repeat testing is allowed at Investigator discretion.
  10. Liver impairment defined as and/or ALT > ; or kidney impairment defined as \< 90 mL/min/1.73m2 using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Creatinine Equation
  11. Clinically significant abnormal physical examination or vital signs as determined by the Investigator.
  12. Clinically significant, abnormal 12 lead as determined by the Investigator, including average > 450 ms for males and >470 ms for females. Note: Repeat testing is allowed at Investigator discretion.
  13. Blood pressure less than 90/40 mmHg or greater than 140/90 mmHg. Heart rate lower than 40 bpm or higher than 99 bpm. Subjects should be seated or semi-supine for a minimum of 5 minutes. Vital signs may be repeated once (once at screening and once at admission) at the discretion of the PI or designee.
  14. History of or positive test result for surface antigen (HBsAg), antibody (HCV Ab), or type 1 (HIV-1) or type 2 (HIV-2) antibody.
  15. Active bacterial or viral infection at screening or the time of admission or COVID 19 test positive at admission
  16. Excessive use of caffeine-containing foods including coffee, tea, cola, energy drinks or chocolates, exceeding 500 mg caffeine/day (approximately 5 cups of coffee or 10 cups of tea), in the opinion of the Investigator during the 7 days before the first administration of the study drug.
  17. Use of or unable to refrain from prescribed medication (with the exception of hormone for women of child bearing potential) or over-the-counter (OTC) medicine (including vitamins, and herbal and dietary supplements, such as St John's Wort) during the 14 days or clearance of 5 half-lives (whichever is longer) before the first administration of the study drug and throughout the study.
  18. Participation in another drug, biologic, or device study, with less than 30 days or less than 5 half-lives from the last dose of investigational product to admission, whichever is longer, except for observational studies.
  19. Use of nicotine-containing products (gum, patch, etc.) within 3 months of Screening (as confirmed by urine cotinine test) and throughout the study; Presence or history within 2 years of screening of smoking or vaping nicotine and throughout the study.
  20. Subject has a presence or history, within 2 years of screening, of alcohol abuse or illicit substance abuse as judged by the Investigator or consumes alcohol or an illicit substance within 48 hours prior to admission and throughout the study.
  21. Presence or history of marijuana use (including prescribed marijuana) within 30 days of Screening and throughout the study
  22. Positive result in the urine alcohol and/or drug screen at screening or at the time of admission.
  23. Veins unsuitable for repeated venipuncture.
  24. Blood donation or blood loss of more than 500 mL within 7 days prior to screening.
  25. In the Investigator's opinion, subject is unable to understand the nature of the study and any risks involved in participation, and unwilling to cooperate and comply with the clinical study protocol procedures, restrictions (dietary or physical activity), and requirements, or is unsuitable for any other reason.

Elderly Cohorts:

Subjects who meet any of the following criteria will be excluded from participating in the study:

  1. Any acute or chronic clinically significant medical condition that is poorly controlled and in the judgement of the Investigator (in consultation with the Sponsor Medical Monitor) could interfere with the safety of the subject or might confound the study results.
  2. Has cancer (Note: subject with history of cancer that is in complete remission and not requiring treatment for at least 5 years, including basal cell carcinoma, squamous cell skin cancer, or melanoma in situ. Superficial skin lesions that have been successfully removed, will not be exclusionary).
  3. Has acute or chronic GI conditions (e.g., gastroesophageal reflux disease, peptic ulcer, active and chronic colitis, cholecystectomy, small or large bowel resection, gastric bypass or equivalent) that would interfere with drug tolerance or absorption.
  4. Has history of migraine headaches requiring medical attention or active treatment within the past 6 months from screening.
  5. Has visible sunburn at admission
  6. Has a history of hypersensitivity/photosensitivity dermatosis within the past 5 years,
  7. Has another active dermatological pathology at screening or admission excluding dry skin or acne, deemed clinically significant by the Investigator.
  8. Has a history of or active ocular pathology or clinically significant findings in the Investigator opinion on ophthalmology exam at screening (Note: normal slit exam (glaucoma, cataract) will be sufficient to exclude sensitivity to phototoxicity). Participants with a history of cataracts that have been corrected may be enrolled, just so long as the corrective procedure took place ≥1 yr prior to screening, and current exam shows no active pathology on screening exam.
  9. Clinically significant abnormalities in results of laboratory tests, such as clinically significant abnormal hematology, clinical chemistry, thyroid, or urinalysis at screening or at the time of admission, as per Investigator's judgment; Note: Repeat testing is allowed at Investigator discretion.
  10. Liver impairment defined as AST and/or ALT > ULN; or kidney impairment defined as eGFR \< 75 mL/min/1.73m2 using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Creatinine Equation at screening.
  11. Clinically significant abnormal physical examination or vital signs as determined by the Investigator.
  12. Clinically significant, abnormal 12 lead ECG as determined by the Investigator, including average QTcF > 450 ms for males and >470 ms for females. Note: Repeat testing is allowed at Investigator discretion.
  13. Blood pressure less than 90/40 mmHg or greater than 140/90 mmHg. Heart rate lower than 40 bpm or higher than 99 bpm. Subjects should be seated or semi-supine for a minimum of 5 minutes. Vital signs may be repeated once (once at screening and once at admission) at the discretion of the PI or designee.
  14. History of or positive test result for hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV Ab), or human immunodeficiency virus type 1 (HIV-1) or type 2 (HIV-2) antibody.
  15. Active bacterial or viral infection at screening or the time of admission or COVID 19 test positive at admission
  16. Excessive use of caffeine-containing foods including coffee, tea, cola, energy drinks or chocolates, exceeding 500 mg caffeine/day (approximately 5 cups of coffee or 10 cups of tea), in the opinion of the Investigator during the 7 days before the first administration of the study drug.
  17. Use of or unable to refrain from prescribed medication or over-the-counter (OTC) medicine (including vitamins, and herbal and dietary supplements, such as St John's Wort) during the 14 days or clearance of 5 half-lives (whichever is longer) before the first administration of the study drug and throughout the study. Subjects taking daily prescription medications for management of acceptable chronic medical conditions (as defined in inclusion criteria #1) will be allowed to continue on these medications but must be on a stable dose, as defined by no change in dose for the 3 months prior to the first dose of study medication and no planned changes during the conduct of the study.
  18. Participation in another investigational drug, biologic, or device study, with less than 30 days or less than 5 half-lives from the last dose of investigational product to admission, whichever is longer, except for observational studies. This reference is specific to participation in a different study involving another investigational drug. This does not apply to the current study where a participant in the SAD phase of the study can also participate in the MAD phase of the study provided they continue to meet all eligibility criteria and a sufficient of 5 half-lives (minimum of 96 hours) takes place between the first dose of the SAD and first dose of the MAD phases.
  19. Use of nicotine-containing products (gum, patch, etc.) within 3 months of Screening (as confirmed by urine cotinine test) and throughout the study; Presence or history within 2 years of screening of smoking or vaping nicotine and throughout the study.
  20. Subject has a presence or history, within 2 years of screening, of alcohol abuse or illicit substance abuse as judged by the Investigator or consumes alcohol or an illicit substance within 48 hours prior to admission and throughout the study.
  21. Presence or history of marijuana use (including prescribed marijuana) within 30 days of Screening and throughout the study
  22. Positive result in the urine alcohol and/or drug screen at screening or at the time of admission.
  23. Veins unsuitable for repeated venipuncture.
  24. Blood donation or blood loss of more than 500 mL within 7 days prior to screening.
  25. In the Investigator's opinion, subject is unable to understand the nature of the study and any risks involved in participation, and unwilling to cooperate and comply with the clinical study protocol procedures, restrictions (dietary or physical activity), and requirements, or is unsuitable for any other reason.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Part 1a Single Ascending Dose (SAD) MF-300

    6 out of 8 participants per cohort (up to 6 cohorts) will be randomized to receive a single dose of MF-300 in a fasted state

    Drug: MF-300 SAD

  • Placebo comparator
    Part 1a Single Ascending Dose (SAD) Placebo

    2 out of 8 participants per cohort (up to 6 cohorts) will be randomized to receive a single oral dose of Placebo in a fasted state

    Drug: Placebo

  • Experimental
    Part 1b Food Effect (Fasted/Fed) MF-300

    12 participants will receive a single dose of MF-300 in fed and fasting conditions

    Drug: MF-300 Food Effect

  • Experimental
    Part 2 Multiple Ascending Dose (MAD) MF-300

    8 out of 10 participants per cohort (up to 4 cohorts) will be randomized to receive once daily oral doses of MF-300 on Days 1-5 in a fasted state

    Drug: MF-300 MAD

  • Placebo comparator
    Part 2 Multiple Ascending Dose (MAD) Placebo

    2 out of 10 participants per cohort (up to 4 cohorts) will be randomized to receive once daily oral doses of Placebo on Days 1-5 in a fasted state

    Drug: Placebo

Interventions

  • DrugMF-300 SAD

    oral capsule at doses of 75mg, 125 mg, 250 mg, 500 mg, or 800 mg

    Also known as: MF-300

  • DrugPlacebo

    matching placebo oral capsule

  • DrugMF-300 Food Effect

    oral capsule at a dose of 500 mg

    Also known as: MF-300

  • DrugMF-300 MAD

    oral capsule at doses of 75mg, 125 mg, or 200 mg

    Also known as: MF-300

06

What researchers measure

Primary outcomes

  1. Proportion of participants with treatment-emergent adverse events (TEAEs)

    Treatment-emergent AEs (TEAEs): AE that either commenced following initiation of study treatment or was present prior to study treatment but increased in frequency or severity following initiation of study treatment

    Time frame: From admission on Day -1 to the Follow-up End of Study Visit (Day 7 for Part 1a, Day 13 for Part 1b, and Day 11 for Part 2)

  2. Proportion of participants with serious adverse events (SAEs)

    An SAE is any untoward medical occurrence at any dose which results in death, is immediately life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event (IME)

    Time frame: From admission on Day -1 to the Follow-up End of Study Visit (Day 7 for Part 1a, Day 13 for Part 1b, and Day 11 for Part 2)

  3. Proportion of participants with any TEAE leading to premature discontinuation of study intervention

    Treatment-emergent AEs (TEAEs): AE that either commenced following initiation of study treatment or was present prior to study treatment but increased in frequency or severity following initiation of study treatment

    Time frame: From admission on Day -1 to the Follow-up End of Study Visit (Day 7 for Part 1a, Day 13 for Part 1b, and Day 11 for Part 2)

Secondary outcomes

  1. Part 1 SAD Cmax

    Plasma PK analysis of maximum observed plasma concentration (Cmax) for MF-300 following a single dose in healthy subjects

    Time frame: up to 72 hours

  2. Part 1 SAD Tmax

    Plasma PK time corresponding to the maximum observed plasma concentration (Tmax) for MF-300 following a single dose in healthy subjects

    Time frame: up to 72 hours

  3. Part 1 SAD t½

    Plasma PK apparent terminal elimination half-life in plasma (t½) for MF-300 following a single dose in healthy subjects

    Time frame: up to 72 hours

  4. Part 1 SAD AUC0-∞

    Plasma PK area under the plasma concentration vs. time curve from time zero extrapolated to infinity (AUC0-∞) for MF-300 following a single dose in healthy subjects

    Time frame: up to 72 hours

  5. Part 2 MAD Cmax

    Plasma PK maximum observed plasma concentration (Cmax) for MF-300 following multiple doses in healthy subjects

    Time frame: up to Day 6

  6. Part 2 MAD Ctrough

    Plasma PK trough plasma concentration (Ctrough) for MF-300 following multiple doses in healthy subjects

    Time frame: up to Day 6

  7. Part 2 MAD Tmax

    Plasma PK time corresponding to the maximum observed plasma concentration (Tmax) for MF-300 following multiple doses in healthy subjects

    Time frame: up to Day 6

  8. Part 2 MAD t½

    Plasma PK Plasma apparent terminal elimination half-life in plasma (t½) for MF-300 following multiple doses in healthy subjects

    Time frame: up to Day 6

  9. Part 2 MAD AUC0-last

    Plasma PK area under the plasma concentration vs. time curve from time zero to last measurable concentration (AUC0-last) for MF-300 following multiple doses in healthy subjects

    Time frame: up to Day 6

07

Study locations

2 sites
  • Site 102
    Marlton, New Jersey 08053, United States
  • Site 101
    Austin, Texas 78744, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2024 to primary completion in Oct 2025, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2026
First posted
May 29, 2026
StartActual
Dec 20, 2024
Primary completionActual
Oct 9, 2025
CompletionActual
Oct 9, 2025
Last update
May 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07613684
Lead sponsor
Epirium Bio Inc.
Responsible party
Sponsor
First posted
May 29, 2026
Start date
Dec 20, 2024
Primary completion
Oct 9, 2025
Completion
Oct 9, 2025
Last update
May 29, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion